Sonoma Pharmaceuticals Inc (SNOA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sonoma Pharmaceuticals Inc (SNOA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11476
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sonoma Pharmaceuticals Inc (Sonoma), formerly Oculus Innovative Sciences, is a pharmaceutical company that develops, manufactures and markets prescription and non-prescription products for the treatment of dermatological conditions and advanced tissue care. The company offers products for advanced wound management, nursing home and home healthcare, wound and skin care, among others. It offers women’s healthcare products, Microcyn skin and wound care products, Regenacyn advanced scar management hydrogel and animal healthcare, among others. Sonoma develops its products based on shelf-stable microcyn technology platform. The company sells its products through OTC stores. The company operates in the Netherlands and the US. Sonoma is headquartered in Petaluma, California, the US.

Sonoma Pharmaceuticals Inc (SNOA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Licensing Agreements 13
Brill Pharma Enters into Licensing Agreement with Sonoma Pharma 13
U.SK Dermatology Enters into Licensing Agreement with Sonoma Pharma 14
Oculus Innovative Amends the Licensing Agreement With Ruthigen 15
AmDerma Pharma Exercises its Option Licensing Agreement With Oculus Innovative Sciences 17
Oculus Innovative Sciences Enters Into Licensing Agreement With More Pharma 18
Equity Offering 19
Sonoma Pharma Prices Public Offering of Units 19
Sonoma Pharma Raises USD5 Million in Public Offering of Shares 20
Oculus Innovative Sciences Raises USD3.26 million in Public Offering Of Shares 22
Oculus Innovative Sciences Raises USD3.4 Million in Public Offering of Units 23
Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 24
Oculus Innovative Sciences Raises USD6.3 Million in Public Offering of Shares and Warrants 25
Oculus Innovative Sciences Raises USD1.35 Million in Private Placement Of Units 27
Oculus Innovative Sciences Completes Private Placement Of Shares For US$2.2 Million 28
Oculus Innovative Sciences Completes Public Offering Of Common Stock For US$3.5 Million 29
Oculus Innovative Sciences Completes Private Placement Of Preferred Stock For US$1 Million 30
Oculus Innovative Sciences Completes Private Placement Of Shares For US$2 Million 31
Asset Transactions 32
Invekra Acquires Latin America Business of Sonoma Pharma for USD22 Million 32
Sonoma Pharmaceuticals Inc – Key Competitors 33
Sonoma Pharmaceuticals Inc – Key Employees 34
Sonoma Pharmaceuticals Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Business Unit 36
Recent Developments 37
Financial Announcements 37
Nov 08, 2018: Sonoma Pharmaceuticals reports record revenue in second quarter FY 2019 37
Aug 08, 2018: Sonoma Pharmaceuticals reports first quarter fy 2019 financial results 39
Jun 13, 2018: Sonoma Pharmaceuticals Announces Fiscal Year And Fourth Quarter 2018 Financial Results 40
Feb 07, 2018: Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% 42
Nov 09, 2017: Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million 44
Aug 08, 2017: Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 46
Feb 09, 2017: Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017 47
Corporate Communications 49
Sep 19, 2018: Sonoma Pharmaceuticals names Phillipe Weigerstorfer as Board Director 49
May 08, 2018: Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer 50
Jan 31, 2017: Sonoma Pharmaceuticals Appoints Marc Umscheid As Chief Strategy And Marketing Officer 51
Other Significant Developments 52
Aug 28, 2018: Sonoma Pharmaceuticals announces results from study of sonoma’s performance-stabilized HOCl (hypochlorous acid) in management of acne vulgaris 52
Jul 13, 2017: Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sonoma Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Brill Pharma Enters into Licensing Agreement with Sonoma Pharma 13
U.SK Dermatology Enters into Licensing Agreement with Sonoma Pharma 14
Oculus Innovative Amends the Licensing Agreement With Ruthigen 15
AmDerma Pharma Exercises its Option Licensing Agreement With Oculus Innovative Sciences 17
Oculus Innovative Sciences Enters Into Licensing Agreement With More Pharma 18
Sonoma Pharma Prices Public Offering of Units 19
Sonoma Pharma Raises USD5 Million in Public Offering of Shares 20
Oculus Innovative Sciences Raises USD3.26 million in Public Offering Of Shares 22
Oculus Innovative Sciences Raises USD3.4 Million in Public Offering of Units 23
Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 24
Oculus Innovative Sciences Raises USD6.3 Million in Public Offering of Shares and Warrants 25
Oculus Innovative Sciences Raises USD1.35 Million in Private Placement Of Units 27
Oculus Innovative Sciences Completes Private Placement Of Shares For US$2.2 Million 28
Oculus Innovative Sciences Completes Public Offering Of Common Stock For US$3.5 Million 29
Oculus Innovative Sciences Completes Private Placement Of Preferred Stock For US$1 Million 30
Oculus Innovative Sciences Completes Private Placement Of Shares For US$2 Million 31
Invekra Acquires Latin America Business of Sonoma Pharma for USD22 Million 32
Sonoma Pharmaceuticals Inc, Key Competitors 33
Sonoma Pharmaceuticals Inc, Key Employees 34
Sonoma Pharmaceuticals Inc, Other Locations 35
Sonoma Pharmaceuticals Inc, Subsidiaries 35
Sonoma Pharmaceuticals Inc, Business Unit 36

List of Figures
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Sonoma Pharmaceuticals Inc (SNOA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Xped Limited (XPE)-エネルギー分野:企業M&A・提携分析
    Summary Xped Limited (Xped) formerly Raya Group Limited, is an Internet of Things company that develops software and hardware solutions. It offers auto discovery remote control, Xerts, and Xped app software; and hardware such as Xped ADRC Shields, Umbo-Xped ADRC Hub, UltraPlug, VariPlug, IRBlaster. …
  • Sodra Skogsagarna ekonomisk forening:企業の戦略的SWOT分析
    Sodra Skogsagarna ekonomisk forening - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Superior Energy Services Inc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Superior Energy Services Inc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Superior Energy Services Inc (Superior Energy) is a provider of equipment and production services to the energy industry. It offers drilling, completion and production-related services to in …
  • China General Plastics Corp (1305):企業の財務・戦略的SWOT分析
    Summary China General Plastics Corp (CGPC), a subsidiary of USI Group is a chemical company that manufactures PVC resins. The company's products include poly vinyl chloride resins, raw materials, vinyl films, films and sheet products, construction products, leather products, and house ware products. …
  • Tractebel Engineering S.A.:企業の戦略的SWOT分析
    Tractebel Engineering S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Central Alabama Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Central Alabama Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Nichii Gakkan Co Ltd (9792):企業の財務・戦略的SWOT分析
    Nichii Gakkan Co Ltd (9792) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Centinel Spine Inc:医療機器:M&Aディール及び事業提携情報
    Summary Centinel Spine Inc (Centinel Spine) is a medical device company that manufactures and markets spinal devices. The company develops integrated interbody fusion technologies. It offers lumbar and cervical solutions. Centinel Spine’s product includes ALTOS, a posterior cervical thoracic stabili …
  • Advanced Accelerator Applications SA (AAAP)-製薬・医療分野:企業M&A・提携分析
    Summary Advanced Accelerator Applications SA (AAA) is a healthcare products provider that offers molecular nuclear medicine and diagnostic and therapeutic products. The company’s lead product candidate comprises Lutathera, a lutetium-177 somatostatin analogue peptide that is used for the treatment o …
  • Franklin Resources Inc:企業の戦略・SWOT・財務分析
    Franklin Resources Inc - Strategy, SWOT and Corporate Finance Report Summary Franklin Resources Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Elekta AB (EKTA B):医療機器:M&Aディール及び事業提携情報
    Summary Elekta AB (Elekta) is a medical technology company that offers image guided and stereotactic clinical solutions, comprehensive information systems and services for the management of brain disorders and improved cancer care. Its major products include Gamma knife and Extend system; stereotact …
  • Impellam Group plc (IPEL):企業の財務・戦略的SWOT分析
    Impellam Group plc (IPEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bangladesh Power Development Board:電力:M&Aディール及び事業提携情報
    Summary Bangladesh Power Development Board (BPDB) is an integrated electric utility. It generates using gas, furnace, diesel, hydro, coal and solar; and imports power from India. The company operates independent power plants /SIPP, rental power plant and REB using steam turbine, gas turbine, combine …
  • Sodexo S.A.:戦略・SWOT・企業財務分析
    Sodexo S.A. - Strategy, SWOT and Corporate Finance Report Summary Sodexo S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • AEON Co Ltd (8267):企業の戦略的SWOT分析
    AEON Co Ltd (8267) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Pivotal Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pivotal Therapeutics Inc (Pivotal Therapeutics) is a pharmaceutical company that develops and markets Omega-3 based therapies and therapeutic products for cardiovascular disorders. The company offers products such as VASCAZEN, a medical food formulated for the dietary management of an Omega- …
  • Vivartia Holdings SA.:戦略・SWOT・企業財務分析
    Vivartia Holdings SA. - Strategy, SWOT and Corporate Finance Report Summary Vivartia Holdings SA. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Petroleos Mexicanos:企業の戦略的SWOT分析
    Petroleos Mexicanos - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Telenor ASA:企業の戦略・SWOT・財務分析
    Telenor ASA - Strategy, SWOT and Corporate Finance Report Summary Telenor ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Atos SE:企業の戦略・SWOT・財務情報
    Atos SE - Strategy, SWOT and Corporate Finance Report Summary Atos SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆